Literature DB >> 22612903

Eosinophilic dermatosis of hematologic malignancy.

Michele J Farber1, Sal La Forgia, Joya Sahu, Jason B Lee.   

Abstract

Cutaneous involvement by an eosinophil-rich process (eosinophilic dermatosis) may be encountered in the setting of various hematologic malignancies, including mantle cell lymphoma, acute monocytic leukemia, acute lymphoblastic leukemia, large cell lymphoma, myelofibrosis and chronic lymphocytic leukemia (CLL). Of the various hematologic malignancies, eosinophilic dermatosis has been most frequently described in association with CLL. Published previously as insect bite-like reaction and eosinophilic dermatosis of myeloproliferative disease, this rare dermatitis presents as a pruritic, papular and occasionally vesicular eruption associated with an eosinophil-rich infiltrate histopathologically. Although clinical and histopathologic features are similar to insect bites, affected patients frequently deny a history of insect bites. We report a case of eosinophilic dermatosis of hematologic malignancy in a patient with known history of CLL.
Copyright © 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22612903     DOI: 10.1111/j.1600-0560.2012.01906.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  11 in total

1.  Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia.

Authors:  Gopisree Peringeth; Suchitra Sundaram; Paul Bogner; Elizabeth Conroy; Pallawi Torka
Journal:  Ann Hematol       Date:  2020-03-19       Impact factor: 3.673

2.  Flame figures associated with eosinophilic dermatosis of hematologic malignancy: is it possible to distinguish the condition from eosinophilic cellulitis in patients with hematoproliferative disease?

Authors:  Jianjun Qiao; Chang-E Sun; Weifang Zhu; Dingxian Zhu; Hong Fang
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

3.  Eosinophilic dermatosis of hematologic malignancy mimicking varicella zoster infection: report in a woman with chronic lymphocytic leukemia and review of the literature.

Authors:  Omar Bari; Philip R Cohen
Journal:  Dermatol Pract Concept       Date:  2017-07-31

4.  Eosinophilic folliculitis in association with chronic lymphocytic leukemia: A clinicopathologic series.

Authors:  Kiran Motaparthi; Jyoti Kapil; Sylvia Hsu
Journal:  JAAD Case Rep       Date:  2017-05-27

5.  Exaggerated arthropod assault: Eosinophilic dermatosis in a patient with small lymphocytic lymphoma.

Authors:  Curtis Lachowiez; Kevin White; Stephen Spurgeon
Journal:  Clin Case Rep       Date:  2018-07-17

6.  Chronic Pruritus Responding to Dupilumab-A Case Series.

Authors:  Lisa L Zhai; Kevin T Savage; Connie C Qiu; Annie Jin; Rodrigo Valdes-Rodriguez; Nicholas K Mollanazar
Journal:  Medicines (Basel)       Date:  2019-06-29

Review 7.  Immune-Mediated Cutaneous Paraneoplastic Syndromes Associated With Hematologic Malignancies: Skin as a Mirror of Hematologic Neoplasms.

Authors:  Jose C Alvarez-Payares; Angel Molina; Simon Gallo; Julian Ramirez; Juan Hernandez; Fernando Lopez; Sara I Ramirez-Urrea; Cristian Álvarez
Journal:  Cureus       Date:  2021-11-13

8.  Eosinophilic folliculitis in a patient with chronic myelomonocytic leukemia.

Authors:  Phalyka Oum; Kerrie G Satcher; Diana Braswell; Marjorie E Montañez-Wiscovich; Kiran Motaparthi
Journal:  JAAD Case Rep       Date:  2019-07-31

9.  Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia.

Authors:  Annie Jin; Bobak T Pousti; Kevin T Savage; Nicholas K Mollanazar; Jason B Lee; Sylvia Hsu
Journal:  JAAD Case Rep       Date:  2019-08-30

Review 10.  Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review.

Authors:  Roberto Maglie; Giovanni Genovese; Farzan Solimani; Alba Guglielmo; Alessandro Pileri; Francesca Portelli; Michael Hertl; Angelo Valerio Marzano; Emiliano Antiga
Journal:  Am J Clin Dermatol       Date:  2020-12       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.